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In the United States, nearly 13% of adults aged 20 years and
older have type 2 diabetes mellitus (T2DM), and its
prevalence is still increasing (1,2). Microvascular and mac-
rovascular abnormalities are common in patients with
T2DM and are related to the severity and duration of
hyperglycemia (3–5). Thus, treatment of hyperglycemia is
an important way to prevent or delay diabetic vascular
complications.
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Several clinical trials have been performed to examine
whether intensive glucose lowering is effective for the
prevention of cardiovascular events (6–8). However, inten-
sive therapy targeting glycosylated hemoglobin levels lower
than 6.0% for 3.5 years paradoxically increased all-cause
mortality and did not significantly reduce major composite
cardiovascular events compared with standard therapy (6).
These findings disclose a previously unrecognized risk for
intensive and rapid glucose lowering in high-risk patients
with T2DM (6,9). However, it is also true that the same
trials confirmed that the incidence of nonfatal myocardial
infarction was significantly lower in the intensive glucose-
lowering group compared with the standard therapy group
(6,7,10). Moreover, the UKPDS 80 (United Kingdom
Prospective Diabetes Study) demonstrated that better con-
trol of blood glucose was associated with continued risk
reduction for microvascular complications, myocardial in-
farction, and all-cause death during 10 years of post-trial
follow-up, a phenomenon called the “legacy effect” (4).
Considering these clinical findings, it is desirable to use
antidiabetic drugs that can effectively lower blood glucose
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relevant to the contents of this paper to disclose.levels but hardly induce hypoglycemia in patients with
T2DM. One such ideal drug class is incretin-related drugs
(11).
There are 2 main incretin hormones, glucose-dependent
insulinotropic peptide (also known as gastric inhibitory
peptide) and glucagon-like peptide (GLP)-1. Both hor-
mones are secreted from endocrine cells located in the
epithelium of the small intestine, triggered by an increase in
the concentration of glucose in the intestinal tract (11).
Incretins stimulate the pancreatic beta cells to secrete insulin
but inhibit alpha cells from releasing glucagon. Thus,
incretins reduce blood glucose levels in an orally taken
glucose–dependent manner, and therefore these drugs
hardly induce hypoglycemia. Both glucose-dependent in-
sulinotropic peptide and GLP-1 are rapidly degraded by a
serine protease, dipeptidyl peptidase (DPP)-4, and the fact
that chemical inhibitors of DPP-4 prevented the degrada-
tion of glucose-dependent insulinotropic peptide and
GLP-1 established the importance of DPP-4 as a critical
determinant of incretin concentrations in vivo (12). Accord-
ingly, 2 classes of incretin-related drugs have been devel-
oped; one is a GLP-1 analogue and the other a DPP-4
inhibitor.
Diabetic states augment reactive oxygen species, inflam-
matory responses, endothelial dysfunction, and lipid depo-
sition in the vascular wall and thereby promote atheroscle-
rosis (13). Thus, drugs that can not only control blood
glucose levels but also inhibit cardiovascular complications
are further desired. In this issue of the Journal, Matsubara et
al. (14) report that a DPP-4 inhibitor, des-fluoro-sitagliptin
(DFS), significantly inhibits atherosclerotic lesion formation in
apolipoprotein E–deficient mice. DFS treatment lowered
blood glucose levels during oral glucose tolerance testing,
restored endothelial function ex vivo, and decreased endothelial
cell senescence and apoptosis in vitro. DFS suppressed inflam-
matory cytokine production in cultured macrophages by en-
hancing the GLP-1-mediated cyclic adenosine monophos-
phate signaling cascade (14). The investigators’ data clearly
indicate that DFS has both glucose-dependent and glucose-
independent actions for antiatherosclerosis.
GLP-1 receptor is expressed in various tissues of the
cardiovascular system (15), and previous studies have shown
that GLP-1 analogues have not only glucose-lowering but
also direct cardioprotective actions (16–18). A GLP-1
analogue, exendin-4, reduced macrophage accumulation in
the arterial wall and thereby inhibited atherosclerotic lesion
formation in apolipoprotein E–deficient mice (16), a similar
animal model used by Matsubara et al. (14). GLP-1 also
protected against myocardial ischemia and reperfusion in-
jury in both animals and humans (17,18). These studies
collectively support the concept that GLP-1 analogues and
their elevating agents, DPP-4 inhibitors, may have direct
cardioprotective actions independent of glucose-lowering
(Fig. 1).
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incretin-independent actions. In other words, DPP-4 has
several important endogenous substrates other than incre-
tins (19). For example, chemokine stromal cell–derived
factor (SDF)-1 and substance P have been known to be
cleaved by DPP-4, and their endogenous concentrations are
significantly affected by DPP-4 inhibitors (19). SDF-1 has
been known to induce angiogenesis in ischemic tissues and
can recruit cardiac or endothelial progenitor cells from the
bone marrow to injured cardiovascular tissues (20–22).
Interestingly, the expression of SDF-1 is decreased within
regenerating tissues in diabetic states (23), indicating that
SDF-1-mediated tissue regenerative actions might be re-
duced in T2DM. In contrast, substance P is a well-known
stimulator of endothelium-derived nitric oxide release (24).
Nitric oxide is a potent vasodilator, inhibiting various
aspects of atherosclerosis, including platelet adherence (25).
DPP-4 inhibitors may stimulate endothelial nitric oxide
release in a substance P–dependent manner as well. Taken
together, DPP-4 inhibitors may provide potential cardio-
protective actions by inhibiting the degradation of SDF-1
and substance P in addition to preserving incretin concen-
trations. These incretin-unrelated mechanisms for cardio-
vascular protection by DPP-4 inhibitors in T2DM are
currently little known and warrant further investigation
(Fig. 1).
Finally, Matsubara et al. (14) measured plasma levels of
GLP-1 activity and found that active GLP-1 levels were
significantly lower in patients with coronary artery disease
Figure 1 The Biological Actions of DPP-4 and
its Significant Endogenous Substrates
Dipeptidyl peptidase (DPP)-4 inhibitors attenuate the degradation of incretins
(glucose-dependent insulinotropic peptide [GIP] and glucagon-like peptide [GLP]-1),
which enhance pancreatic insulin secretion and inhibit glucagon secretion,
resulting in blood glucose lowering. Incretins have direct and indirect (glucose
lowering–dependent) antiatherosclerotic and cardioprotective effects. DPP-4
inhibitors also attenuate degradation of chemokine stromal cell–derived factor
(SDF)-1 and substance P, which may elicit antiatherosclerotic and cardioprotec-
tive actions as well through a variety of mechanisms. However, the latter possi-
bilities of biological action of DPP-4 inhibitors need further investigation.than in those without. Their data are consistent with thefact that the prevalence of T2DM is more common in
patients with coronary artery disease compared with those
without (26). However, it is still unknown whether plasma
GLP-1 level is a major determinant of atherosclerotic
disease burden in patients with T2DM. Although the
investigators show a significant inverse correlation between
plasma GLP-1 activity and the area of atherosclerotic
lesions in the apolipoprotein E–deficient mice (14), this
relation is still unknown for humans. Clearly, additional
basic research and clinical studies are necessary to further
address the antiatherogenic efficacy of DPP-4 inhibitors.
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